- Home
- KPTI vs SURG Comparison
KPTI vs SURG Comparison
Compare KPTI & SURG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- SURG
- Stock Information
- Founded
- KPTI 2008
- SURG 2006
- Country
- KPTI United States
- SURG United States
- Employees
- KPTI N/A
- SURG N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- SURG Advertising
- Sector
- KPTI Health Care
- SURG Consumer Discretionary
- Exchange
- KPTI Nasdaq
- SURG Nasdaq
- Market Cap
- KPTI 33.6M
- SURG 27.0M
- IPO Year
- KPTI 2013
- SURG N/A
- Fundamental
- Price
- KPTI $4.21
- SURG $2.47
- Analyst Decision
- KPTI Strong Buy
- SURG Strong Buy
- Analyst Count
- KPTI 5
- SURG 1
- Target Price
- KPTI $61.00
- SURG $8.50
- AVG Volume (30 Days)
- KPTI 172.5K
- SURG 4.8M
- Earning Date
- KPTI 05-07-2025
- SURG 05-12-2025
- Dividend Yield
- KPTI N/A
- SURG N/A
- EPS Growth
- KPTI N/A
- SURG N/A
- EPS
- KPTI N/A
- SURG N/A
- Revenue
- KPTI $145,237,000.00
- SURG $60,881,173.00
- Revenue This Year
- KPTI $4.87
- SURG $59.57
- Revenue Next Year
- KPTI $16.29
- SURG $75.47
- P/E Ratio
- KPTI N/A
- SURG N/A
- Revenue Growth
- KPTI N/A
- SURG N/A
- 52 Week Low
- KPTI $3.51
- SURG $1.05
- 52 Week High
- KPTI $21.30
- SURG $4.38
- Technical
- Relative Strength Index (RSI)
- KPTI 37.33
- SURG 68.42
- Support Level
- KPTI $3.83
- SURG $2.18
- Resistance Level
- KPTI $4.36
- SURG $2.47
- Average True Range (ATR)
- KPTI 0.55
- SURG 0.41
- MACD
- KPTI 0.13
- SURG 0.02
- Stochastic Oscillator
- KPTI 25.64
- SURG 61.54
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; Lead Generation is a generation and case management solutions company serving law firms in the mass tort industry; and Others. It generates the revenue from Mobile Virtual Network Operator segment.